Last summer this pharmaceutical company was a single-digit stock but it has been on tear since. The stock did pull in sharply after topping out in the upper 80s in early March, but it has responded well and looks like it could be setting up for another leg higher.
Trading Plan: Stop: below $68 Entry: break of wedge Target: $78 then $86